How US Hemp Ban Could Criminalize CBD Products – and Derail Medicare Plan

The recent push by Congress to ban hemp, citing concerns over THC levels, has created a perfect storm of confusion and contamination that threatens not only the future of hemp-derived products but also our understanding of cannabis. At its core, this issue is about a lack of comprehension regarding the nature of plant-based substances.

The Centers for Medicare and Medicaid Services’ (CMS) new pilot program to reimburse patients for hemp-derived products like CBD has sparked concern among lawmakers, who claim that a ban on hemp would derail the initiative. However, the real issue is not just the efficacy of these products but also the safety of the industry as a whole.

The 2018 Farm Bill created a loophole allowing for the sale of cannabis products with less than .3% delta nine THC, leading to a proliferation of hemp-derived products on the market. However, an impending ban would criminalize “the vast majority” of these products, including non-intoxicating CBD, as Jonathan Miller of US Hemp Roundtable pointed out.

The issue is complicated by lawmakers’ lack of understanding about the endocannabinoid system and cannabis product chemistry. Inesa Ponomariovaite, owner of Nesa’s Hemp, recently met with members of Congress to advocate for laws that would keep her products legal. She noted that she had to explain the concept of the endocannabinoid system to senators unfamiliar with it.

This lack of understanding is not only frustrating but also worrying. As Ponomariovaite pointed out, hemp-derived products are often contaminated with micro-toxins, metals, and other pollutants. A Forbes Health investigation found mold, yeast, and fungicide in some popular CBD products, highlighting the need for stricter regulations on the industry.

The proposed Cannabinoid Safety and Regulation Act would replace the ban with regulation to ensure hemp products are safe and free of contaminants. However, it’s unclear whether this legislation will pass through Congress given its current polarized state.

Advocates like Ponomariovaite argue that lawmakers should focus on contamination rather than dissecting the cannabis plant into parts that are legal and parts that are not. Hemp itself has natural soil-cleaning properties, but if extracted for medicinal purposes, it can be loaded with toxins. Quality controls on hemp products are not universal, and laws like the Cannabinoid Safety and Regulation Act would make it possible for the FDA to regulate these products.

The outcome of this situation remains uncertain, but one thing is clear: the hemp ban conundrum highlights a systemic issue in our approach to cannabis regulation. Rather than trying to prohibit or restrict certain aspects of the industry, we need to take a more comprehensive and nuanced approach that prioritizes safety, quality control, and education.

As the November 12th deadline approaches, when the ban is set to go into effect, one thing is certain: if lawmakers don’t act soon, they will be left with a mess on their hands. And it’s not just hemp-derived products that are at risk – our understanding of cannabis and its potential therapeutic benefits are also in jeopardy.

In this perfect storm of confusion and contamination, we need clear heads and strong leadership to navigate the complex web of laws, regulations, and public opinion surrounding hemp and cannabis. The fate of these plant-based substances hangs in the balance, and it’s up to us to ensure that their potential is not squandered by a lack of understanding and poor decision-making.

The clock is ticking – will we act soon enough to save the future of hemp-derived products, or will we be left with a legacy of missed opportunities and unfulfilled promises? The answer lies in our collective ability to confront the confusion and contamination head-on and forge a new path forward.